Publications by Steinar Aamdal

91 publications found

Publications in press

1. Brandberg Y, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J
   Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
   Eur J Cancer (in press)
   PubMed 22196968
2. Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EG, Barriuso J, Sandhu S, Tan DS, Hartog V, Kuenen B, Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E
   Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
   Br J Cancer (in press)
   PubMed 22531637

Publications 2011

1. Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011)
   Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
   Clin Cancer Res, 17 (21), 6847-57
   PubMed 21918169
2. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG et al. (2011)
   Defining the critical hurdles in cancer immunotherapy
   J Transl Med, 9 (1), 214
   PubMed 22168571
3. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D (2011)
   A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
   J Transl Med, 9, 204
   PubMed 22123319
4. Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H, Nordic Melanoma Cooperative Group (2011)
   Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
   Lancet Oncol, 12 (2), 144-52
   PubMed 21256809
5. Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S (2011)
   Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients
   Clin Cancer Res, 17 (13), 4568-80
   PubMed 21586625
6. Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G (2011)
   hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
   Cancer Immunol Immunother, 60 (6), 809-18
   PubMed 21365467
7. Zwierzina H, Bergmann L, Fiebig H, Aamdal S, Schöffski P, Witthohn K, Lentzen H (2011)
   The preclinical and clinical activity of aviscumine: a potential anticancer drug
   Eur J Cancer, 47 (10), 1450-7
   PubMed 21482461
8. Aamdal S (2011)
   Current approaches to adjuvant therapy of melanoma
   Eur J Cancer, 47 Suppl 3, S336-7
   PubMed 21944005

Publications 2010

1. Edvardsen H, Brunsvig PF, Solvang H, Tsalenko A, Andersen A, Syvanen AC, Yakhini Z, Børresen-Dale AL, Olsen H, Aamdal S, Kristensen VN (2010)
   SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance
   Pharmacogenomics J, 10 (6), 513-23
   PubMed 20157331
2. Prasmickaite L, Skrbo N, Høifødt HK, Suo Z, Engebråten O, Gullestad HP, Aamdal S, Fodstad Ø, Maelandsmo GM (2010)
   Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells
   Pigment Cell Melanoma Res, 23 (3), 449-51
   PubMed 20236249

Publications 2009

1. Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM, EORTC Melanoma Group and the Nordic Melanoma Group (2009)
   Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon
   J Natl Cancer Inst, 101 (12), 869-77
   PubMed 19509353
2. Dueland S, Aamdal S, Lind MJ, Thomas H, Sandvold ML, Gaullier JM, Rasch W (2009)
   Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study
   Acta Oncol, 48 (1), 137-45
   PubMed 18607882
3. Gunnes N, Seierstad TG, Aamdal S, Brunsvig PF, Jacobsen AB, Sundstrøm S, Aalen OO (2009)
   Assessing quality of life in a randomized clinical trial: correcting for missing data
   BMC Med Res Methodol, 9, 28
   PubMed 19405936

Publications 2008

1. Brunsvig PF, Flatmark K, Aamdal S, Høifødt H, Le H, Jakobsen E, Sandstad B, Fodstad O (2008)
   Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients
   Lung Cancer, 61 (2), 170-6
   PubMed 18261824
2. Faye RS, Paus E, Maelandsmo GM, Berner A, Høifødt HK, Fodstad Ø, Aamdal S (2008)
   S100B in bone marrow aspirates in healthy individuals and malignant melanoma patients
   Melanoma Res, 18 (2), 134-40
   PubMed 18337650
3. Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S, Langmark F, Loeb M, Akslen LA, Molven A, Andresen PA (2008)
   Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas
   Genes Chromosomes Cancer, 47 (2), 175-84
   PubMed 18023021

Publications 2007

1. Brunsvig PF, Andersen A, Aamdal S, Kristensen V, Olsen H (2007)
   Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy
   BMC Cancer, 7, 197
   PubMed 17956601
2. Hernberg M, Mattila PS, Rissanen M, Hansson J, Aamdal S, Bastholt L, von der Maase H, Schmidt H, Stierner U, Tarkkanen J (2007)
   The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma
   J Immunother, 30 (7), 773-9
   PubMed 17893569
3. Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, Gaudernack G (2007)
   T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
   Cancer Immunol Immunother, 56 (5), 659-75
   PubMed 16947019

Publications 2006

1. Andersen A, Warren DJ, Brunsvig PF, Aamdal S, Kristensen GB, Olsen H (2006)
   High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection
   BMC Clin Pharmacol, 6, 2
   PubMed 16412237
2. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Møller M, Eriksen JA, Gaudernack G (2006)
   Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
   Cancer Immunol Immunother, 55 (12), 1553-64
   PubMed 16491401
3. Jacobsen KD, Fosså SD, Aamdal S (2006)
   [Malignant melanoma--diagnosis and treatment]
   Tidsskr Nor Laegeforen, 126 (23), 3094-7
   PubMed 17160112
4. Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, Gaudernack G (2006)
   Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
   Cancer Gene Ther, 13 (10), 905-18
   PubMed 16710345
5. Warloe T, Aamdal S, Reith A, Bryne M (2006)
   [Retraction of: Diagnostics and treatment of early stages of oral cancer]
   Tidsskr Nor Laegeforen, 126 (17), 2287
   PubMed 16967079

Publications 2005

1. Brunsvig PF, Hatlevoll R, Berg R, Lauvvang G, Owre K, Wang M, Aamdal S (2005)
   Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: a phase I/II study with 5 years' follow-up
   Lung Cancer, 50 (1), 97-105
   PubMed 16005105
2. Kyte JA, Kvalheim G, Aamdal S, Saebøe-Larssen S, Gaudernack G (2005)
   Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination
   Cancer Gene Ther, 12 (6), 579-91
   PubMed 15818380
3. Millward MJ, Joshua A, Kefford R, Aamdal S, Thomson D, Hersey P, Toner G, Lynch K (2005)
   Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma
   Invest New Drugs, 23 (3), 253-6
   PubMed 15868382
4. Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G (2005)
   Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
   Br J Cancer, 93 (7), 749-56
   PubMed 16136047
5. Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Schöffski P, Gore M, Lesimple T, Djurasinovic N, Baron B, Ravic M, Fumoleau P, Punt CJ, EORTC New Drug Development and Melanoma Groups (2005)
   Phase II study of E7070 in patients with metastatic melanoma
   Ann Oncol, 16 (1), 158-61
   PubMed 15598954
6. Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group (2005)
   Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen)
   Lung Cancer, 48 (2), 251-61
   PubMed 15829326

Publications 2004

1. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y (2004)
   Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study
   J Clin Oncol, 22 (6), 1118-25
   PubMed 15020614
2. Bos AM, Boom K, Vinks AA, Boezen HM, Wanders J, Dombernovsky P, Aamdal S, de Vries EG, Uges DR (2004)
   Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755
   Cancer Chemother Pharmacol, 54 (1), 64-70
   PubMed 15069581
3. Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, Rogatko A (2004)
   Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936
   J Clin Oncol, 22 (4), 602-9
   PubMed 14966084
4. Faye RS, Aamdal S, Høifødt HK, Jacobsen E, Holstad L, Skovlund E, Fodstad Ø (2004)
   Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients
   Clin Cancer Res, 10 (12 Pt 1), 4134-9
   PubMed 15217950
5. Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S (2004)
   Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial
   J Clin Oncol, 22 (5), 801-10
   PubMed 14990635

Publications 2003

1. Bremnes RM, Sundstrom S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S, Norweigian Lung Cancer Study Group (2003)
   The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up
   Lung Cancer, 39 (3), 303-13
   PubMed 12609569
2. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G (2003)
   Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
   Eur J Cancer, 39 (1), 70-7
   PubMed 12504661

Publications 2002

1. Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group (2002)
   Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up
   J Clin Oncol, 20 (24), 4665-72
   PubMed 12488411

Publications 2001

1. Bos AM, de Vries EG, Dombernovsky P, Aamdal S, Uges DR, Schrijvers D, Wanders J, Roelvink MW, Hanauske AR, Bortini S, Capriati A, Crea AE, Vermorken JB (2001)
   Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours
   Cancer Chemother Pharmacol, 48 (5), 361-9
   PubMed 11761453
2. Fodstad O, Faye R, Høifødt HK, Skovlund E, Aamdal S (2001)
   Immunobead-based detection and characterization of circulating tumor cells in melanoma patients
   Recent Results Cancer Res, 158, 40-50
   PubMed 11092032
3. Hovig E, Myklebost O, Aamdal S, Smeland EB (2001)
   [Gene therapy in cancer]
   Tidsskr Nor Laegeforen, 121 (4), 482-8
   PubMed 11255868
4. Sudbø J, Warloe T, Aamdal S, Reith A, Bryne M (2001)
   [Diagnosis and treatment of oral precancerous lesions]
   Tidsskr Nor Laegeforen, 121 (26), 3066-71 (Retracted)
   PubMed 11757442

Publications 2000

1. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000)
   Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
   J Clin Oncol, 18 (1), 158-66
   PubMed 10623706
2. Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, Punt C, Verweij J, van Oosterom A, Morant R, Wanders J, Hanauske AR (2000)
   Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)
   Cancer Chemother Pharmacol, 46 (2), 167-71
   PubMed 10972487
3. Aamdal S, Lund B, Koier I, Houten M, Wanders J, Verweij J (2000)
   Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)
   Cancer Chemother Pharmacol, 45 (1), 85-8
   PubMed 10647507

Publications 1998

1. Jungnelius U, Ringborg U, Aamdal S, Mattsson J, Stierner U, Ingvar C, Malmström P, Andersson R, Karlsson M, Willman K, Wist E, Bjelkengren G, Westberg R (1998)
   Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial
   Eur J Cancer, 34 (9), 1368-74
   PubMed 9849419
2. Semb KA, Aamdal S, Bohmann T, Lucas C, Gerard B (1998)
   Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma
   Melanoma Res, 8 (6), 565-72
   PubMed 9918419
3. Semb KA, Aamdal S, Mette E, Ingvar C, Gullaksen N, Osmundsen K (1998)
   Zilascorb(H-2), a low-toxicity protein synthesis inhibitor that exhibits signs of anticancer activity in malignant melanoma
   Anti-Cancer Drugs, 9 (9), 797-802
4. Semb KA, Aamdal S, Mette E, Ingvar C, Gullaksen N, Osmundsen K (1998)
   Zilascorb(2H), a low-toxicity protein synthesis inhibitor that exhibits signs of anticancer activity in malignant melanoma
   Anticancer Drugs, 9 (9), 797-802
   PubMed 9840726
5. Semb KA, Aamdal S, Oian P (1998)
   Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment
   J Clin Oncol, 16 (10), 3426-32
   PubMed 9779722

Publications 1997

1. Semb KA, Fodstad O, Klem B, Bibow K, Osmundsen K, Aamdal S (1997)
   Zilascorb(H-2), a new reversible protein synthesis inhibitor: Clinical study of an oral preparation
   Anti-Cancer Drugs, 8 (3), 296-303
2. Semb KA, Fodstad O, Klem B, Bibow K, Osmundsen K, Aamdal S (1997)
   Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation
   Anticancer Drugs, 8 (3), 296-303
   PubMed 9095337
3. Aamdal S, Bruntsch U, Kerger J, Verweij J, ten Bokkel Huinink W, Wanders J, Rastogi R, Franklin HR, Kaye SB (1997)
   Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity
   Cancer Chemother Pharmacol, 40 (5), 439-43
   PubMed 9272122

Publications 1996

1. Hanauske AR, Catimel G, Aamdal S, ten Bokkel Huinink W, Paridaens R, Pavlidis N, Kaye SB, te Velde A, Wanders J, Verweij J (1996)
   Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group
   Br J Cancer, 73 (3), 397-9
   PubMed 8562349
2. Karlsson M, Jungnelius U, Aamdal S, Boeryd B, Carstensen J, Kågedal B, Westberg R, Wingren S (1996)
   Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanoma
   Int J Cancer, 65 (1), 1-5
   PubMed 8543385
3. McLeod HL, Graham MA, Aamdal S, Setanoians A, Groot Y, Lund B (1996)
   Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group
   Eur J Cancer, 32A (9), 1518-22
   PubMed 8911111
4. McLeod HL, Murray LS, Wanders J, Setanoians A, Graham MA, Pavlidis N, Heinrich B, ten Bokkel Huinink WW, Wagener DJ, Aamdal S, Verweij J (1996)
   Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups
   Br J Cancer, 74 (12), 1944-8
   PubMed 8980394
5. Semb KA, Aamdal S, Fosså SD, Oian P (1996)
   Transcapillary forces of the subcutaneous tissue in patients treated with interleukin-2 and alpha-interferon: no capillary protein leak syndrome?
   J Exp Ther Oncol, 1 (3), 155-61
   PubMed 9414399

Publications 1995

1. Fosså SD, Aamdal S, Naume B, Gallati H (1995)
   Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-alpha combination therapy
   Acta Oncol, 34 (5), 599-603
   PubMed 7546824
2. Verweij J, Catimel G, Sulkes A, Sternberg C, Wolff I, Aamdal S, van Hoesel Q (1995)
   Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group
   Eur J Cancer, 31A Suppl 4, S21-4
   PubMed 7577101

Publications 1994

1. Sessa C, Aamdal S, Wolff I, Eppelbaum R, Smyth JF, Sulkes A, Ten Bokkel Huinink W, Vermorken J, Wanders J, Franklin H (1994)
   Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group
   Ann Oncol, 5 (5), 471-2
   PubMed 8075055
2. Verweij J, Aamdal S, Schellens J, Koier I, Lund B (1994)
   Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group
   Oncol Res, 6 (10-11), 519-23
   PubMed 7620220
3. Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, Wanders J, Franklin HR, Verweij J (1994)
   Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group
   Eur J Cancer, 30A (8), 1061-4
   PubMed 7654429

Publications 1993

1. Gerard B, Aamdal S, Lee SM, Leyvraz S, Lucas C, D'Incalci M, Bizzari JP (1993)
   Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma
   Eur J Cancer, 29A (5), 711-9
   PubMed 8471329
2. Lundby B, Berg KJ, Lien HH, Aamdal S (1993)
   A double blind study to evaluate the tolerability of gadodiamide injection and its effect on renal function in patients undergoing cerebral magnetic resonance imaging
   Br J Radiol, 66 (790), 871-6
   PubMed 8220968

Publications 1992

1. Beiske K, Myklebust AT, Aamdal S, Langholm R, Jakobsen E, Fodstad O (1992)
   Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods
   Am J Pathol, 141 (3), 531-8
   PubMed 1381558
2. Flørenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O (1992)
   Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression
   Cancer Res, 52 (21), 6088-91
   PubMed 1356624
3. Wibe E, Hannisdal E, Paus E, Aamdal S (1992)
   Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma
   Eur J Cancer, 28A (10), 1692-5
   PubMed 1389487
4. Aamdal S (1992)
   Can ondansetron hydrochloride (Zofran) enhance the nephrotoxic potential of other drugs?
   Ann Oncol, 3 (9), 774
   PubMed 1450070
5. Aamdal S, Gerard B, Bohman T, D'Incalci M (1992)
   Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity
   Eur J Cancer, 28 (2-3), 447-50
   PubMed 1591062

Publications 1991

1. Myklebust AT, Beiske K, Pharo A, Davies CD, Aamdal S, Fodstad O (1991)
   Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasis
   Br J Cancer Suppl, 14, 49-53
   PubMed 1645572
2. Stoter G, Aamdal S, Rodenhuis S, Cleton FJ, Iacobelli S, Franks CR, Oskam R, Shiloni E (1991)
   Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study
   J Clin Oncol, 9 (9), 1687-91
   PubMed 1875225

Publications 1990

1. Tefre T, Børresen AL, Aamdal S, Brøgger A (1990)
   Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients
   Br J Cancer, 61 (6), 809-12
   PubMed 1973618
2. Wibe E, Paus E, Aamdal S (1990)
   Neuron specific enolase (NSE) in serum of patients with malignant melanoma
   Cancer Lett, 52 (1), 29-31
   PubMed 2354416

Publications 1989

1. Stoter G, Shiloni E, Aamdal S, Cleton FJ, Iacobelli S, Bijman JT, Palmer P, Franks CR, Rodenhuis S (1989)
   Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study
   Eur J Cancer Clin Oncol, 25 Suppl 3, S41-3
   PubMed 2697578

Publications 1988

1. Fodstad O, Kjønniksen I, Aamdal S, Nesland JM, Boyd MR, Pihl A (1988)
   Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells
   Cancer Res, 48 (15), 4382-8
   PubMed 3390834
2. Fodstad O, Aamdal S, McMenamin M, Nesland JM, Pihl A (1988)
   A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX
   Int J Cancer, 41 (3), 442-9
   PubMed 3346110
3. Aamdal S, Fodstad O, Pihl A (1988)
   Sodium thiosulfate fails to increase the therapeutic index of intravenously administered cis-diamminedichloroplatinum (II) in mice bearing murine and human tumors
   Cancer Chemother Pharmacol, 21 (2), 129-33
   PubMed 3349560

Publications 1987

1. Gundersen S, Aamdal S, Fodstad O (1987)
   Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease
   Br J Cancer, 55 (4), 433-5
   PubMed 3580266
2. Aamdal S, Fodstad O, Pihl A (1987)
   Some procedures to reduce cis-platinum toxicity reduce antitumour activity
   Cancer Treat Rev, 14 (3-4), 389-95
   PubMed 3326670

Publications 1986

1. Aamdal S, Fodstad O, Kaalhus O, Pihl A (1986)
   Chemosensitivity profiles of human cancers assessed by the 6-day SRC assay on serially xenografted tumors
   Int J Cancer, 37 (4), 579-87
   PubMed 3957463

Publications 1985

1. Fodstad O, Aamdal S, Pihl A, Boyd MR (1985)
   Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas
   Cancer Res, 45 (4), 1778-86
   PubMed 3978640
2. Aamdal S, Fodstad O, Nesland JM, Pihl A (1985)
   Characteristics of human tumour xenografts transplanted under the renal capsule of immunocompetent mice
   Br J Cancer, 51 (3), 347-56
   PubMed 3970811
3. Aamdal S, Fodstad O, Pihl A (1985)
   Methodological aspects of the 6-day subrenal capsule assay for measuring the response of human tumors to anticancer agents
   Anticancer Res, 5 (4), 329-37
   PubMed 4037730
4. Aamdal S, Fodstad O, Pihl A (1985)
   The six-day subrenal capsule assay (SRCA) for testing the response of human tumours to anticancer agents. Validity and usefulness in cancer research and treatment
   Ann Chir Gynaecol Suppl, 199, 51-9
   PubMed 3864392

Publications 1984

1. Fodstad O, Kvalheim G, Godal A, Lotsberg J, Aamdal S, Høst H, Pihl A (1984)
   Phase I study of the plant protein ricin
   Cancer Res, 44 (2), 862-5
   PubMed 6692385
2. Aamdal S, Børmer O, Jørgensen O, Høst H, Eliassen G, Kaalhus O, Pihl A (1984)
   Estrogen receptors and long-term prognosis in breast cancer
   Cancer, 53 (11), 2525-9
   PubMed 6713348
3. Aamdal S, Fodstad O, Kaalhus O, Pihl A (1984)
   Reduced antineoplastic activity in mice of cisplatin administered with high salt concentration in the vehicle
   J Natl Cancer Inst, 73 (3), 743-52
   PubMed 6590919
4. Aamdal S, Fodstad O, Pihl A (1984)
   Human tumor xenografts transplanted under the renal capsule of conventional mice. Growth rates and host immune response
   Int J Cancer, 34 (5), 725-30
   PubMed 6500747